Factors contributing to the emergence of coronary thrombolysis.
Coronary thrombosis is now recognized as the most common proximate cause of acute myocardial infarction, and thrombolysis is evolving as an accepted therapeutic approach to patients presenting in the early stages of myocardial infarction. The ascent of thrombolysis in treatment hierarchies reflects multiple factors, including improved understanding of the pathophysiology of myocardial infarction, advances in the characterization of thrombosis and thrombolysis, the availability of clot-selective thrombolytic agents, the widespread availability of safe arteriographic procedures, and the contemporaneous development of effective percutaneous balloon angioplasty. Selection of patients most likely to benefit from thrombolysis with the lowest risk for complications remains difficult. Undoubtedly, some patients will benefit greatly from an aggressive approach to evolving myocardial infarction.
D000818:Animals; D003328:Coronary Thrombosis / Q000188:drug therapy; D005342:Fibrinolysis / Q000187:drug effects; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000503:physiopathology; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator